As GH promotes lymphangiogenesis and the corresponding markers in PDAC correlate with GHR expression in our analyses, it can be expected that GHRAs can lower or inhibit tumor lymphangiogenesis to attenuate tumor growth, which remains to be tested in PDAC. This evidence concerns the gene GH1 and neoplasm.